Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 299

1.

pSTAT3 Levels Have Divergent Expression Patterns and Associations with Survival in Squamous Cell Carcinoma and Adenocarcinoma of the Oesophagus.

O' Sullivan KE, Michielsen AJ, O' Regan E, Cathcart MC, Moore G, Breen E, Segurado R, Reynolds JV, Lysaght J, O' Sullivan J.

Int J Mol Sci. 2018 Jun 10;19(6). pii: E1720. doi: 10.3390/ijms19061720.

2.

International consensus on a complications list after gastrectomy for cancer.

Baiocchi GL, Giacopuzzi S, Marrelli D, Reim D, Piessen G, Matos da Costa P, Reynolds JV, Meyer HJ, Morgagni P, Gockel I, Lara Santos L, Jensen LS, Murphy T, Preston SR, Ter-Ovanesov M, Fumagalli Romario U, Degiuli M, Kielan W, Mönig S, Kołodziejczyk P, Polkowski W, Hardwick R, Pera M, Johansson J, Schneider PM, de Steur WO, Gisbertz SS, Hartgrink H, van Sandick JW, Portolani N, Hölscher AH, Botticini M, Roviello F, Mariette C, Allum W, De Manzoni G.

Gastric Cancer. 2018 May 30. doi: 10.1007/s10120-018-0839-5. [Epub ahead of print]

PMID:
29846827
3.

Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review.

O'Neill L, Moran J, Guinan EM, Reynolds JV, Hussey J.

J Cancer Surviv. 2018 May 23. doi: 10.1007/s11764-018-0696-6. [Epub ahead of print] Review.

PMID:
29796931
4.

Multicentre randomized clinical trial of inspiratory muscle training versus usual care before surgery for oesophageal cancer.

Valkenet K, Trappenburg JCA, Ruurda JP, Guinan EM, Reynolds JV, Nafteux P, Fontaine M, Rodrigo HE, van der Peet DL, Hania SW, Sosef MN, Willms J, Rosman C, Pieters H, Scheepers JJG, Faber T, Kouwenhoven EA, Tinselboer M, Räsänen J, Ryynänen H, Gosselink R, van Hillegersberg R, Backx FJG.

Br J Surg. 2018 Apr;105(5):502-511. doi: 10.1002/bjs.10803.

PMID:
29603130
5.

Patient experiences of a physiotherapy-led multidisciplinary rehabilitative intervention after successful treatment for oesophago-gastric cancer.

Bennett AE, O'Neill L, Connolly D, Guinan EM, Boland L, Doyle SL, O'Sullivan J, Reynolds JV, Hussey J.

Support Care Cancer. 2018 Feb 18. doi: 10.1007/s00520-018-4112-6. [Epub ahead of print]

PMID:
29455302
6.

Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma.

Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, O'Sullivan KE, Doherty DG, Geoghegan JG, Ravi N, O'Farrelly C, Reynolds JV, Lysaght J.

Cancer Lett. 2018 Apr 1;418:230-238. doi: 10.1016/j.canlet.2018.01.039. Epub 2018 Jan 12.

PMID:
29339209
7.

Multidisciplinary rehabilitation across the esophageal cancer journey.

O'Neill L, Gannon J, Guinan E, Reynolds JV, Hussey J.

J Thorac Dis. 2017 Dec;9(12):E1140-E1142. doi: 10.21037/jtd.2017.11.72. No abstract available.

8.

Benchmarking Complications Associated with Esophagectomy.

Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G, Davies A, D'Journo XB, Gisbertz SS, Griffin SM, Hardwick R, Hoelscher A, Hofstetter W, Jobe B, Kitagawa Y, Law S, Mariette C, Maynard N, Morse CR, Nafteux P, Pera M, Pramesh CS, Puig S, Reynolds JV, Schroeder W, Smithers M, Wijnhoven BPL.

Ann Surg. 2017 Dec 4. doi: 10.1097/SLA.0000000000002611. [Epub ahead of print]

PMID:
29206677
9.

Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

Guinan EM, Doyle SL, Bennett AE, O'Neill L, Gannon J, Elliott JA, O'Sullivan J, Reynolds JV, Hussey J.

Support Care Cancer. 2018 May;26(5):1569-1576. doi: 10.1007/s00520-017-3993-0. Epub 2017 Dec 2.

PMID:
29197960
10.

Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?

Sheil F, Donohoe CL, King S, O'Toole D, Cunningham M, Cuffe S, Ravi N, Reynolds JV.

World J Surg. 2018 May;42(5):1485-1495. doi: 10.1007/s00268-017-4289-8.

PMID:
29075858
11.

Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking.

Prichard DO, Byrne AM, Murphy JO, Reynolds JV, O'Sullivan J, Feighery R, Doyle B, Eldin OS, Finn SP, Maguire A, Duff D, Kelleher DP, Long A.

J Cell Mol Med. 2017 Dec;21(12):3612-3625. doi: 10.1111/jcmm.13271. Epub 2017 Sep 22.

12.

Impact of supplemental home enteral feeding postesophagectomy on nutrition, body composition, quality of life, and patient satisfaction.

Donohoe CL, Healy LA, Fanning M, Doyle SL, Hugh AM, Moore J, Ravi N, Reynolds JV.

Dis Esophagus. 2017 Sep 1;30(9):1-9. doi: 10.1093/dote/dox063.

PMID:
28859364
13.

Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials.

Donohoe CL, Reynolds JV.

J Thorac Dis. 2017 Jul;9(Suppl 8):S697-S704. doi: 10.21037/jtd.2017.03.159. Review.

14.

Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.

Elliott JA, Doyle SL, Murphy CF, King S, Guinan EM, Beddy P, Ravi N, Reynolds JV.

Ann Surg. 2017 Nov;266(5):822-830. doi: 10.1097/SLA.0000000000002398.

PMID:
28796017
15.

Does Prolonged Enteral Feeding With Supplemental Omega-3 Fatty Acids Impact on Recovery Post-esophagectomy: Results of a Randomized Double-Blind Trial.

Healy LA, Ryan A, Doyle SL, Ní Bhuachalla ÉB, Cushen S, Segurado R, Murphy T, Ravi N, Donohoe CL, Reynolds JV.

Ann Surg. 2017 Nov;266(5):720-728. doi: 10.1097/SLA.0000000000002390.

PMID:
28742713
16.

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).

Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM.

BMC Cancer. 2017 Jun 3;17(1):401. doi: 10.1186/s12885-017-3386-2.

17.

Reduced fitness and physical functioning are long-term sequelae after curative treatment for esophageal cancer: a matched control study.

Gannon JA, Guinan EM, Doyle SL, Beddy P, Reynolds JV, Hussey J.

Dis Esophagus. 2017 Aug 1;30(8):1-7. doi: 10.1093/dote/dox018.

PMID:
28575241
18.

Impact of visceral obesity and metabolic syndrome on the postoperative immune, inflammatory, and endocrine response following surgery for esophageal adenocarcinoma.

Doyle SL, Mongan AM, Donohoe CL, Pidgeon GP, Sherlock M, Reynolds JV, Lysaght J.

Dis Esophagus. 2017 Jun 1;30(6):1-11. doi: 10.1093/dote/dox008.

PMID:
28475745
19.

HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.

Dunne MR, Michielsen AJ, O'Sullivan KE, Cathcart MC, Feighery R, Doyle B, Watson JA, O'Farrell NJ, Ravi N, Kay E, Reynolds JV, Ryan EJ, O'Sullivan J.

Cancer Immunol Immunother. 2017 Jul;66(7):841-850. doi: 10.1007/s00262-017-1983-1. Epub 2017 Mar 18.

20.

Home enteral nutrition recipients: patient perspectives on training, complications and satisfaction.

Boland K, Maher N, O'Hanlon C, O'Sullivan M, Rice N, Smyth M, Reynolds JV.

Frontline Gastroenterol. 2017 Jan;8(1):79-84. doi: 10.1136/flgastro-2016-100736. Epub 2016 Oct 8. No abstract available.

Supplemental Content

Loading ...
Support Center